TKNO
Alpha Teknova, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$6.92
−4.42%Year over year
Reported trailing growth
- Revenue
- +12.3%
- EBITDA
- +34.5%
- EBIT
- +26.1%
- EPS
- +27.4%
- Free cash flow
- +31.9%
- Operating cash flow
- +34.0%
Forward estimates
Based on analyst estimates
- Revenue
- +11.1%
- EBITDA
- +17.1%
- EPS
- +5.1%
Three-year CAGR
- Revenue
- -0.7%
- EBITDA
- +48.1%
- EBIT
- +35.1%
- Net income
- +35.5%
- EPS
- +43.9%
- Free cash flow
- +27.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026